Kona Pharma

Executive Summary

Kona Pharma AG is a Swiss contract development and manufacturing organization (CDMO) focused on solid dosage forms, with a special license for narcotics. Integrated into the Rhenopharma Group, it serves pharmaceutical clients from its large-scale facility in Pratteln, Switzerland. The company offers development, production, clinical sample manufacturing, and packaging services. While Kona Pharma has a stable position in the European CDMO market, its growth prospects are tied to capacity expansion and securing long-term contracts. The company is privately held, with no disclosed financials, making it a lower-conviction investment target compared to publicly traded CDMOs. However, its narcotics license provides a niche advantage.

Upcoming Catalysts (preview)

• 2027Facility expansion or capacity upgrade at Pratteln site60% success
• 2026New long-term manufacturing contract with a major pharma company50% success
• 2026-2027Expansion of narcotics manufacturing capabilities (new license or product line)40% success